ClinicalTrials.gg
CompletedNCT06161220Updated Mar 5, 2024

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

A Phase 1 interventional study of Carbidopa capsule and Moxifloxacin Tablets, USP in Cardiac Repolarization in Healthy Subjects, sponsored by Impax Laboratories, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.

02

Conditions studied

  • Cardiac Repolarization in Healthy Subjects
03

In context

Lead sponsor

Impax Laboratories, LLC is the lead sponsor of 20 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.

First submitted after Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females aged 18 to 55 years (both inclusive)
  • For female subjects of , use of double method
  • (BMI) 18.5 to \<30 kg/m² at Screening, with a minimum weight of 55kg
  • Subject with no abnormal serum biochemistry, hematology and urine examination values at screening
  • Subject with negative urine screen for drugs of abuse at screening
  • Subject with negative (HIV), surface antigen (Hep B) and virus antibody (Hep C) results at screening
  • Subject must be willing to communicate with the investigator and site staff and comply with all study procedures and requirements
  • Subject must be able to provide written, including compliance with the requirements listed in the consent form
  • Subject must be able and willing to swallow whole capsules without breaking, cutting, or chewing

Exclusion criteria

Exclusion Criteria:

  • History or presence of systemic diseases at Screening, which as judged by the investigator, may affect the outcome of this study, include, but not limited to significant: cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
  • Female subjects who are pregnant or lactating
  • Knowledge of any kind of cardiovascular disorder/condition known to increase the possibility of or history of additional risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome or Brugada Syndrome) or cardiac conduction disorders
  • Resting supine heart rate less than 50 beats per minute or greater than 100 beats per minute
  • Resting supine systolic blood pressure less than 90 mmHg or greater than 140 mmHg; resting supine diastolic blood pressure less than 50 mmHg or greater than 90 mmHg.
  • (as determined by the Investigator) abnormalities at Screening, including:

    1. QTcF > 450 ms for female and >430 ms for male
    2. QRS > 110 ms
    3. PR > 200 ms
    4. QTcF > 450 ms for female and >430 for male
    5. QRS > 110 ms
    6. PR > 200 ms
    7. Resting supine HR \<50 beats per minute (bpm) or >100 bpm (may be repeated once at the discretion of the investigator)
    8. Second or third-degree AV block
    9. Any rhythm other than sinus rhythm, which is interpreted by the Investigator to be clinically significant
    10. Bundle Branch Block
    11. premature atrial and ventricular contractions,
    12. nonspecific T-wave changes
  • Positive urine/serum drug screen at Screening or Day -1 for each Period
  • History of significant alcohol abuse or drug abuse within one year prior to Screening.
  • Use of prescription medication (with the exception of medically approved hormonal ) including MAO inhibitors in the 30 days prior to admission into Period 1 and over-the-counter medications including vaccines, vitamins, and herbal remedies within 14 days prior to admission of Period 1 till completion of the study (EOS or ET)
  • History of unexplained loss of consciousness, unexplained syncope, unexplained irregular heartbeats or palpitations or near drowning with hospital admission
  • Subjects who received any drug within the longer of 30 days or 5 half-lives of Day 1 dosing of SM
  • Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study
  • Use of medications in the 90 days before admission of the study that are known to prolong the QT/QTc interval.
  • Family history of QTc prolongation or of unexplainable sudden death at \<50 years of age. For this study, family is defined as 1st degree relative (i.e., mother, father, siblings, children) or 2nd degree relative (grandparents, grandchildren, half-siblings, aunt/uncle, niece/nephew).
  • Subjects who cannot refrain from using tobacco of any kind within 30 days prior to admission (Day -1) of Period 1 until the last blood sample collection of study
  • Subjects who cannot refrain from consumption of alcohol or alcohol containing products or xanthine-containing foods or beverages (like chocolate, tea, coffee or cola drinks) within 48 hours prior to admission (Day -1) of Period 1 till the last blood sample collection of study
  • Subjects who participate in other drug research study during the study.
  • Subjects who cannot refrain from donating blood or plasma for 30 days and 14 days (respectively) prior to dosing, during the study, and for at least 4 weeks after completing the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Carbidopa capsule

    Dose: 4x 100 mg

    Drug: Carbidopa capsule · Drug: Moxifloxacin Tablets, USP · Drug: Placebo

  • Active comparator
    Moxifloxacin Tablets, USP

    Dose: 400 mg

    Drug: Carbidopa capsule · Drug: Moxifloxacin Tablets, USP · Drug: Placebo

  • Placebo comparator
    Placebo

    Drug: Carbidopa capsule · Drug: Moxifloxacin Tablets, USP · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline QTcF (ΔQTcF)

    Change-from-baseline QTcF ( QTcF) will allow evaluation of the effects of carbidopa and moxifloxacin on cardiac repolarization based on model derived placebo-corrected ΔQTcF (ΔΔQTcF).

    Time frame: Predose to 24 hours postdose

Secondary outcomes

  1. Change from baseline HR, PR, and QRS

    Change from baseline HR, PR, and QRS (ΔHR, ΔPR, ΔQRS) will also be measured to allow evaluation of the effects of carbidopa and moxifloxacin on other ECG parameters based on model derived placebo-corrected ΔHR, ΔPR, and ΔQRS (ΔΔHR, ΔΔPR, and ΔΔQRS).

    Time frame: Predose to 24 hours postdose

07

Study locations

1 site
  • AXIS Clinicals, LLC
    Dilworth, Minnesota 56529-1342, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Dec 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 7, 2023
StartActual
Oct 30, 2023
Primary completionActual
Dec 3, 2023
CompletionActual
Dec 5, 2023
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06161220
Responsible party
Sponsor
First posted
Dec 7, 2023
Start date
Oct 30, 2023
Primary completion
Dec 3, 2023
Completion
Dec 5, 2023
Last update
Mar 5, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carbidopa

Start the discussion